ArticleGenes & cancer2016

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.

Satoshi Matsusaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.